Nonpolynucleotide Inducers of Interferon

  • D. A. Stringfellow
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 71)


Following the discovery of interferon, a great deal of interest centered around developing methods of clinically utilizing this interesting material. During the 1950s and early 1960s, attention was given to the problem of producing interferon in cultured cells in vitro which could be purified and concentrated for exogenous transfer to the exposed or infected host. In the early 1960s, a small number of workers became interested in the possibility that an animal’s own cells could be stimulated to produce their own endogenous interferon in vivo. These studies were stimulated by the discovery of Steinebring and Youngner (1964) that an extract of gram-negative organisms, a lipopolysacchride (endotoxin), would induce a detectable interferon response when injected into mice. Consequently, interest centered around the potential use of molecules such as lipopolysaccharide to induce detectable levels of interferon in vivo.


Antitumor Activity Antiviral Activity Semliki Forest Virus Interferon Response Encephalomyocarditis Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Einhorn S, Strander H (1977) Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J Gen Virol 35:573–580PubMedCrossRefGoogle Scholar
  2. Fast PE, Stringfellow DA (1980) Immune modulation by two antiviral isocytosines with different abilities to induce interferon. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease. Am Soc Microbiol Washington DC, pp 1396–1398Google Scholar
  3. Field AK, Tytell AA, Lampson GP, Hilleman MR (1967) Inducers of interferon and host resistance, II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 58:1004–1010PubMedCrossRefGoogle Scholar
  4. Gatmaitan BG, Stanley ED, Jackson GG (1973) The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J Infect Dis 127:401–407PubMedCrossRefGoogle Scholar
  5. Glaz ET, Szologay E, Stoger I, Talas M (1973) Antiviral activity and induction of interferon-like substance by Quinacrine and Acranil. Antimicrob Agents Chemother 3:537PubMedGoogle Scholar
  6. Hill DA, Baran S, Levy HB, Bellanti J, Buckler CE (1971) Clinical studies of induction of interferon by polyinosinic-polycytidylic acid. Perspect Virol 7:197–222Google Scholar
  7. Hoffman WW, Korst JJ, Niblack JF, Cronin TH (1973) N, N-dioctadecyl-N′, N′-bis(2-hy-droxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob Agents Chemother 3:498PubMedGoogle Scholar
  8. Kaufman HE, Centifanto YM, Ellison ED, Brown DC (1971) Tilorone hydrochloride: human toxicity and interferon stimulation. Proc Soc Exp Biol Med 137:357–360PubMedGoogle Scholar
  9. Mayer GD, Krueger RF (1970) Tilorone hydrochloride: mode of action. Science 169:1214PubMedCrossRefGoogle Scholar
  10. Merigan TC, Reed SE, Hall TS, Tyrell D (1973) Inhibition of respiratory virus infection by locally applied interferon. Lancet i: 563–566CrossRefGoogle Scholar
  11. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP (1978) Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New Engl J Med 18:981–987CrossRefGoogle Scholar
  12. Panusarn C, Stanley ED, Dirda V, Rubenis M, Jackson GG (1974) Prevention of illness from rhino virus infection by a topical interferon inducer. New Engl J Med 291:57–61PubMedCrossRefGoogle Scholar
  13. Renis HE, Eidson EE (1980) Protection of mice from herpes simplex virus infection by 5-halo, 6-arylisocytosines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease. Am Soc Microbiol, Washington, DCGoogle Scholar
  14. Strander H, Cantell K, Jakobsson PA, Nilsonne U, Soderber G (1974) Exogenous interferon therapy of osteogenic sarcoma. Acta Orthop Scand 45:958–961Google Scholar
  15. Steinenbring WR, Youngner JS (1964) Patterns of interferon appearance in mice injected with bacteria or bacterial endotoxin. Nature 204:712CrossRefGoogle Scholar
  16. Strander H, Einhorn S (1977) Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 19:468–473PubMedCrossRefGoogle Scholar
  17. Strander H, Adamson U, Aparisi T, Broström A, Cantell K, Einhorn S, Hall K, Ingimarsson S, Nilsonne U, Soderberg G (1979) Adjuvant interferon treatment of human osteosarcoma. In: Bonadonna G, Mathe G, Salmon SE (eds) Adjuvant therapies and markers of post-surgical minimal residual disease II. Springer, Berlin Heidelberg New York, pp 40–44 (Recent results in cancer research, vol 68)CrossRefGoogle Scholar
  18. Stringfellow DA, Weed SD, Underwood GE (1979) Antiviral and interferon-inducing properties of 1,5-diamino anthraquinones. Antimicrob Agents Chemother 15:111PubMedGoogle Scholar
  19. Stringfellow DA, Vanderberg HC, Weed SD (1980) Interferon induction by 5-halo-6-phenyl pyrimidinones. J Interferon Res 1:1–16PubMedCrossRefGoogle Scholar
  20. Stringfellow DA (1980) Interferon inducers: theory and experimental application. In: Stringellow DA (ed) Interferon and interferon inducers: clinical applications. Dekker, New York, pp 145–164Google Scholar
  21. Wierenga W, Skulnick HI, Stringfellow DA, Weed SD, Renis HE, Eidson EE (1979) 5-Substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents. J Med Chem 23:237–239CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • D. A. Stringfellow

There are no affiliations available

Personalised recommendations